Mineralized vectors for gene therapy
Source abstract
Abstract
There is an intense interest in developing materials for safe and effective delivery of polynucleotides using non-viral vectors. Mineralization of organic templates has long been used to produce complex materials with outstanding biocompatibility. However, a lack of control over mineral growth has limited the applicability of mineralized materials to a few in vitro applications. With better control over mineral growth and surface functionalization, mineralized vectors have advanced significantly in recent years. Here, we review the recent progress in chemical synthesis, physicochemical properties, and applications of mineralized materials in gene therapy, focusing on structure-function relationships. We contrast the classical understanding of the mineralization mechanism with recent ideas of mineralization. A brief introduction to gene delivery is summarized, followed by a detailed survey of current mineralized vectors. The vectors derived from calcium phosphate are articulated and compared to other minerals with unique features. Advanced mineral vectors derived from templated mineralization and specialty coatings are critically analyzed. Mineral systems beyond the co-precipitation are explored as more complex multicomponent systems. Finally, we conclude with a perspective on the future of mineralized vectors by carefully demarcating the boundaries of our knowledge and highlighting ambiguous areas in mineralized vectors. STATEMENT OF SIGNIFICANCE: Therapy by gene-based medicines is increasingly utilized to cure diseases that are not alleviated by conventional drug therapy. Gene medicines, however, rely on macromolecular nucleic acids that are too large and too hydrophilic for cellular uptake. Without tailored materials, they are not functional for therapy. One emerging class of nucleic acid delivery system is mineral-based materials. The fact that they can undergo controlled dissolution with minimal footprint in biological systems are making them attractive for clinical use, where safety is utmost importance. In this submission, we will review the emerging synthesis technology and the range of new generation minerals for use in gene medicines.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: RNA Interference and Gene Delivery · Virus-based gene therapy research · Advanced biosensing and bioanalysis techniques
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Gene therapy for cancer: present status and future perspective10.1186/2052-8426-2-27 ↗
2. Advances in combining gene therapy with cell and tissue engineering-based approaches to enhance healing of the meniscus10.1016/j.joca.2016.03.018 ↗
3. Gene therapy comes of age10.1126/science.aan4672 ↗
4. Gene Therapy for Human Genetic Disease?10.1126/science.175.4025.949 ↗
5. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells10.1038/35078107 ↗
6. RNA interference in adult mice10.1038/418038a ↗
7. Therapeutic application of RNAi: is mRNA targeting finally ready for prime time?10.1172/JCI34129 ↗
8. Advances in Non-Viral DNA Vectors for Gene Therapy10.3390/genes8020065 ↗
9. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer10.1016/j.ymgme.2003.08.016 ↗
10. Emerging patent landscape for non-viral vectors used for gene therapy10.1038/s41587-019-0402-x ↗
11. Zwitterion-functionalized dendrimer-entrapped gold nanoparticles for serum-enhanced gene delivery to inhibit cancer cell metastasis10.1016/j.actbio.2019.09.005 ↗
12. Carbon nanotubes as vectors for gene therapy: past achievements, present challenges and future goals10.1016/j.addr.2013.10.003 ↗
13. Gene therapy progress and prospects: magnetic nanoparticle-based gene delivery10.1038/sj.gt.3302720 ↗
14. Toxicity of cationic lipids and cationic polymers in gene delivery10.1016/j.jconrel.2006.04.014 ↗
15. Biodegradable calcium phosphate nanoparticles for cancer therapy10.1016/j.cis.2020.102157 ↗
16. Calcium phosphates in biomedical applications: materials for the future?10.1016/j.mattod.2015.10.008 ↗
17. Optimizing conditions for calcium phosphate mediated transient transfection10.1016/j.sjbs.2017.01.034 ↗
18. Devising new lipid-coated calcium phosphate/carbonate hybrid nanoparticles for controlled release in endosomes for efficient gene delivery10.1039/C7TB01635B ↗
19. Dual-functionalized calcium carbonate based gene delivery system for efficient gene delivery10.1039/C4RA05468G ↗
20. Lipid-Coated, pH-Sensitive Magnesium Phosphate Particles for Intracellular Protein Delivery10.1007/s11095-019-2607-6 ↗
21. DNA-encapsulated magnesium phosphate nanoparticles elicit both humoral and cellular immune responses in mice10.1016/j.rinim.2014.04.001 ↗
22. L. Jin, X. Zeng, M. Liu, Y. Deng, N. He, Current Progress in Gene Delivery Technology Based on Chemical Methods and Nano-carriers, Theranostics. 4 (2014) 240–255. doi:10.7150/thno.6914.10.7150/thno.6914 ↗
23. Bioinspired negatively charged calcium phosphate nanocarriers for cardiac delivery of MicroRNAs10.2217/nnm.16.26 ↗
24. Galactose Derivative-Modified Nanoparticles for Efficient siRNA Delivery to Hepatocellular Carcinoma10.1021/acs.biomac.8b00358 ↗
25. Systemic delivery of siRNA by hyaluronan-functionalized calcium phosphate nanoparticles for tumor-targeted therapy10.1039/C6NR04034A ↗
26. Oncolytic Adenovirus Complexes Coated with Lipids and Calcium Phosphate for Cancer Gene Therapy10.1021/acsnano.6b06182 ↗
27. Kinetische Behandlung der Keimbildung in übersättigten Dämpfen10.1002/andp.19354160806 ↗
28. A General Theory of Heterophase Fluctuations and Pretransition Phenomena10.1063/1.1750484 ↗
29. Keimbildung in übersättigten Gebilden10.1515/zpch-1926-11927 ↗
30. Ion-association complexes unite classical and non-classical theories for the biomimetic nucleation of calcium phosphate10.1038/ncomms2490 ↗
31. The two-step mechanism of nucleation of crystals in solution10.1039/c0nr00628a ↗
32. Pre-nucleation clusters as solute precursors in crystallisation10.1039/C3CS60451A ↗
33. A classical view on nonclassical nucleation10.1073/pnas.1700342114 ↗
34. Stable Prenucleation Calcium Carbonate Clusters10.1126/science.1164271 ↗
35. Synthetic amorphous calcium phosphate and its relation to bone mineral structure10.1021/ar50092a003 ↗
36. The role of prenucleation clusters in surface-induced calcium phosphate crystallization10.1038/nmat2900 ↗
37. Cluster Growth Model for Hydroxyapatite10.1021/cm980062c ↗
38. Dissolving Hydroxyolite: a DNA Molecule into Its Hydroxyapatite Mold10.1002/chem.201600703 ↗
39. Modification of nanostructured calcium carbonate for efficient gene delivery10.1016/j.colsurfb.2014.03.007 ↗
40. Calcium phosphate nanoparticles with an asymmetric lipid bilayer coating for siRNA delivery to the tumor10.1016/j.jconrel.2011.10.020 ↗
41. Concentration of viral vectors by co-precipitation with calcium phosphate10.1002/1521-2254(2000)9999:9999<::AID-JGM159>3.0.CO;2-9 ↗
42. Controllable synthesis of calcium silicate nanoparticles through one-step microemulsion method for drug and gene delivery10.1166/nnl.2017.2391 ↗
43. Enhanced delivery of siRNA to triple negative breast cancer cells in vitro and in vivo through functionalizing lipid-coated calcium phosphate nanoparticles with dual target ligands10.1039/C7NR08644J ↗
44. Magnetically deliverable calcium phosphate nanoparticles for localized gene expression10.1039/C4RA13413C ↗
45. Organelle-specific targeting of polymersomes into the cell nucleus10.1073/pnas.1916395117 ↗
46. RNA interference in human cells is restricted to the cytoplasm10.1017/S1355838202020071 ↗
47. Minicircle DNA Provides Enhanced and Prolonged Transgene Expression Following Airway Gene Transfer10.1038/srep23125 ↗
48. Effects of Circular DNA Length on Transfection Efficiency by Electroporation into HeLa Cells10.1371/journal.pone.0167537 ↗
49. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency10.1093/nar/27.19.3792 ↗
50. Rational Vector Design for Efficient Non-viral Gene Delivery: challenges Facing the Use of Plasmid DNA10.1007/s12033-008-9046-7 ↗
51. Chitosan Nanoparticles for Nuclear Targeting: the Effect of Nanoparticle Size and Nuclear Localization Sequence Density10.1021/acs.molpharmaceut.5b00478 ↗
52. How successful is nuclear targeting by nanocarriers?10.1016/j.jconrel.2016.03.022 ↗
53. Requirements for the nuclear entry of polyplexes and nanoparticles during mitosis10.1002/jgm.2669 ↗
54. siRNA Versus miRNA as Therapeutics for Gene Silencing10.1038/mtna.2015.23 ↗
55. Endocytosis of nanomedicines10.1016/j.jconrel.2010.01.036 ↗
56. Niedergang · 2016 · 751
57. Nanoparticle opsonization: forces involved and protection by long chain polymers10.1007/s00289-019-02924-7 ↗
58. Role of particle size in phagocytosis of polymeric microspheres10.1007/s11095-008-9562-y ↗
59. Effects of particle size and surface charge on cellular uptake and biodistribution of polymeric nanoparticles10.1016/j.biomaterials.2010.01.065 ↗
60. Swanson · 2016 · 758
61. Nano-Structural Effects on Gene Transfection: large, Botryoid-Shaped Nanoparticles Enhance DNA Delivery via Macropinocytosis and Effective Dissociation10.7150/thno.30302 ↗
62. Size-dependent cellular uptake mechanism and cytotoxicity toward calcium oxalate on Vero cells10.1038/srep41949 ↗
63. Virus entry by macropinocytosis10.1038/ncb0509-510 ↗
64. Mechanisms of clathrin-mediated endocytosis10.1038/nrm.2017.132 ↗
65. F.P. G., W.S. E., P.D. S., L.M. P., Caveolin, Caveolae, and Endothelial Cell Function, Arteriosclerosis, Thrombosis, and Vascular Biology. 23 (2003) 1161–1168. doi:10.1161/01.ATV.0000070546.16946.3A.10.1161/01.ATV.0000070546.16946.3A ↗
66. Endocytosis unplugged: multiple ways to enter the cell10.1038/cr.2010.19 ↗
67. Insight into Cellular Uptake and Intracellular Trafficking of Nanoparticles10.1186/s11671-018-2728-6 ↗
68. Cellular uptake of nanoparticles: journey inside the cell10.1039/C6CS00636A ↗
69. The endosomal-lysosomal system: from acidification and cargo sorting to neurodegeneration10.1186/s40035-015-0041-1 ↗
70. Intracellular trafficking pathways involved in the gene transfer of nano-structured calcium phosphate-DNA particles10.1016/j.biomaterials.2011.01.043 ↗
71. Lipid-coated nano-calcium-phosphate (LNCP) for gene delivery10.1016/j.ijpharm.2010.03.012 ↗
72. The proton sponge hypothesis: fable or fact?10.1016/j.ejpb.2018.05.034 ↗
73. Dynamics of crystallization and dissolution of calcium orthophosphates at the near-molecular level10.1007/s11434-010-4184-2 ↗
74. Understanding biophysicochemical interactions at the nano–bio interface10.1038/nmat2442 ↗
75. Protein Corona-Mediated Mitigation of Cytotoxicity of Graphene Oxide10.1021/nn200021j ↗
76. Protein Corona Influences Cell–Biomaterial Interactions in Nanostructured Tissue Engineering Scaffolds10.1002/adfm.201500875 ↗
77. Biomolecular coronas provide the biological identity of nanosized materials10.1038/nnano.2012.207 ↗
78. Transferrin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface10.1038/nnano.2012.237 ↗
79. Rapid formation of plasma protein corona critically affects nanoparticle pathophysiology10.1038/nnano.2013.181 ↗
80. Controlling evolution of protein corona: a prosperous approach to improve chitosan-based nanoparticle biodistribution and half-life10.1038/s41598-020-66572-y ↗
81. Influence of Size and Shape on the Biodistribution of Nanoparticles Prepared by Polymerization-Induced Self-Assembly10.1021/acs.biomac.7b00995 ↗
82. Identifying Trends in Gold Nanoparticle Toxicity and Uptake: size, Shape, Capping Ligand, and Biological Corona10.1021/acsomega.8b03227 ↗
83. Effects of the Presence or Absence of a Protein Corona on Silica Nanoparticle Uptake and Impact on Cells10.1021/nn300223w ↗
84. The Evolution of the Protein Corona around Nanoparticles: a Test Study10.1021/nn202458g ↗
85. Size-Dependent Endocytosis of Nanoparticles10.1002/adma.200801393 ↗
86. Virus-inspired design principles of nanoparticle-based bioagents10.1371/journal.pone.0013495 ↗
87. Determining the size and shape dependence of gold nanoparticle uptake into mammalian cells10.1021/nl052396o ↗
88. A quantum dot conjugated sugar ball and its cellular uptake. on the size effects of endocytosis in the subviral region10.1021/ja048792a ↗
89. Size effect on cell uptake in well-suspended, uniform mesoporous silica nanoparticles10.1002/smll.200900005 ↗
90. Elucidating the mechanism of cellular uptake and removal of protein-coated gold nanoparticles of different sizes and shapes10.1021/nl070363y ↗
91. Size-dependent endocytosis of gold nanoparticles studied by three-dimensional mapping of plasmonic scattering images10.1186/1477-3155-8-33 ↗
92. Size-dependent cellular uptake and localization profiles of silver nanoparticles10.2147/IJN.S201107 ↗
93. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction10.2217/nnm.16.5 ↗
94. Effect of particle size on the biodistribution, toxicity, and efficacy of drug-loaded polymeric nanoparticles in chemoradiotherapy10.1016/j.nano.2017.03.002 ↗
95. Size matters for in vitro gene delivery: investigating the relationships among complexation protocol, transfection medium, size and sedimentation10.1038/srep44134 ↗
96. Unexpected Size Effect: the Interplay between Different-Sized Nanoparticles in Their Cellular Uptake
97. The shape effect of PEGylated mesoporous silica nanoparticles on cellular uptake pathway in Hela cells10.1016/j.micromeso.2012.05.040 ↗
98. The effect of shape on cellular uptake of gold nanoparticles in the forms of stars, rods, and triangles10.1038/s41598-017-04229-z ↗
99. The effect of particle design on cellular internalization pathways10.1073/pnas.0801763105 ↗
100. Shape and surface effects on the cytotoxicity of nanoparticles: gold nanospheres versus gold nanostars10.1002/jbm.a.35491 ↗